Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review.
<h4>Introduction</h4>K-ras gene mutations were common in colorectal patients, but their relationship with prognosis was unclear.<h4>Objective</h4>Verify prognostic differences between patient with and without mutant K-ras genes by reviewing the published evidence.<h4>Me...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0077901 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850116022200172544 |
|---|---|
| author | Yuan-Yi Rui Dan Zhang Zong-Guang Zhou Cun Wang Lie Yang Yong-Yang Yu Hai-Ning Chen |
| author_facet | Yuan-Yi Rui Dan Zhang Zong-Guang Zhou Cun Wang Lie Yang Yong-Yang Yu Hai-Ning Chen |
| author_sort | Yuan-Yi Rui |
| collection | DOAJ |
| description | <h4>Introduction</h4>K-ras gene mutations were common in colorectal patients, but their relationship with prognosis was unclear.<h4>Objective</h4>Verify prognostic differences between patient with and without mutant K-ras genes by reviewing the published evidence.<h4>Method</h4>Systematic reviews and data bases were searched for cohort/case-control studies of prognosis of colorectal cancer patients with detected K-ras mutations versus those without mutant K-ras genes, both of whom received chemotherapy. Number of patients, regimens of chemotherapy, and short-term or long-term survival rate (disease-free or overall) were extracted. Quality of studies was also evaluated.<h4>Principal findings</h4>7 studies of comparisons with a control group were identified. No association between K-ras gene status with neither short-term disease free-survival (OR=1.01, 95% CI, 0.73-1.38, P=0.97) nor overall survival (OR=1.06, 95% CI, 0.82-1.36, P=0.66) in CRC patients who received chemotherapy was indicated. Comparison of long-term survival between two groups also indicated no significant difference after heterogeneity was eliminated (OR=1.09, 95% CI, 0.85-1.40, P=0.49).<h4>Conclusions</h4>K-ras gene mutations may not be a prognostic index for colorectal cancer patients who received chemotherapy. |
| format | Article |
| id | doaj-art-e7c9f73e73c64a0e90636c8f4bc1eac5 |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-e7c9f73e73c64a0e90636c8f4bc1eac52025-08-20T02:36:26ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01810e7790110.1371/journal.pone.0077901Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review.Yuan-Yi RuiDan ZhangZong-Guang ZhouCun WangLie YangYong-Yang YuHai-Ning Chen<h4>Introduction</h4>K-ras gene mutations were common in colorectal patients, but their relationship with prognosis was unclear.<h4>Objective</h4>Verify prognostic differences between patient with and without mutant K-ras genes by reviewing the published evidence.<h4>Method</h4>Systematic reviews and data bases were searched for cohort/case-control studies of prognosis of colorectal cancer patients with detected K-ras mutations versus those without mutant K-ras genes, both of whom received chemotherapy. Number of patients, regimens of chemotherapy, and short-term or long-term survival rate (disease-free or overall) were extracted. Quality of studies was also evaluated.<h4>Principal findings</h4>7 studies of comparisons with a control group were identified. No association between K-ras gene status with neither short-term disease free-survival (OR=1.01, 95% CI, 0.73-1.38, P=0.97) nor overall survival (OR=1.06, 95% CI, 0.82-1.36, P=0.66) in CRC patients who received chemotherapy was indicated. Comparison of long-term survival between two groups also indicated no significant difference after heterogeneity was eliminated (OR=1.09, 95% CI, 0.85-1.40, P=0.49).<h4>Conclusions</h4>K-ras gene mutations may not be a prognostic index for colorectal cancer patients who received chemotherapy.https://doi.org/10.1371/journal.pone.0077901 |
| spellingShingle | Yuan-Yi Rui Dan Zhang Zong-Guang Zhou Cun Wang Lie Yang Yong-Yang Yu Hai-Ning Chen Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review. PLoS ONE |
| title | Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review. |
| title_full | Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review. |
| title_fullStr | Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review. |
| title_full_unstemmed | Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review. |
| title_short | Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review. |
| title_sort | can k ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy a meta analysis and systematic review |
| url | https://doi.org/10.1371/journal.pone.0077901 |
| work_keys_str_mv | AT yuanyirui cankrasgenemutationbeutilizedasprognosticbiomarkerforcolorectalcancerpatientsreceivingchemotherapyametaanalysisandsystematicreview AT danzhang cankrasgenemutationbeutilizedasprognosticbiomarkerforcolorectalcancerpatientsreceivingchemotherapyametaanalysisandsystematicreview AT zongguangzhou cankrasgenemutationbeutilizedasprognosticbiomarkerforcolorectalcancerpatientsreceivingchemotherapyametaanalysisandsystematicreview AT cunwang cankrasgenemutationbeutilizedasprognosticbiomarkerforcolorectalcancerpatientsreceivingchemotherapyametaanalysisandsystematicreview AT lieyang cankrasgenemutationbeutilizedasprognosticbiomarkerforcolorectalcancerpatientsreceivingchemotherapyametaanalysisandsystematicreview AT yongyangyu cankrasgenemutationbeutilizedasprognosticbiomarkerforcolorectalcancerpatientsreceivingchemotherapyametaanalysisandsystematicreview AT hainingchen cankrasgenemutationbeutilizedasprognosticbiomarkerforcolorectalcancerpatientsreceivingchemotherapyametaanalysisandsystematicreview |